Comparative Pharmacology
Head-to-head clinical analysis: DEXTROMETHORPHAN POLISTIREX versus PROVAL 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXTROMETHORPHAN POLISTIREX versus PROVAL 3.
DEXTROMETHORPHAN POLISTIREX vs PROVAL #3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextromethorphan polistirex is an NMDA receptor antagonist and sigma-1 receptor agonist. It inhibits serotonin reuptake and acts on the brain stem cough center to elevate the threshold for coughing.
Proval #3 is a combination of acetaminophen (paracetamol), butalbital, and caffeine. Acetaminophen inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis in the CNS, raising the pain threshold. Butalbital is a barbiturate that enhances GABA-A receptor activity, producing sedation and anxiolysis. Caffeine is a CNS stimulant that potentiates analgesic effects via adenosine receptor antagonism.
30-60 mg orally every 12 hours; not to exceed 120 mg in 24 hours.
1-2 tablets orally every 4-6 hours as needed for pain; not to exceed 8 tablets per day.
None Documented
None Documented
Terminal half-life: 13–19 hours; clinical context: extended-release formulation due to polistirex complex; time to steady-state: ~3 days
4–6 hours in adults with normal hepatic function; prolonged in hepatic impairment (8–12 hours).
Renal: ~45% as unchanged drug and metabolites (dextrorphan conjugates); fecal: <2%; biliary: minimal
Primarily hepatic metabolism (CYP450) with <5% excreted unchanged in urine. Biliary/fecal elimination accounts for ~15% as metabolites.
Category C
Category C
Antitussive
Antitussive